The correct treatment and management of infection by Coronavirus (COVID-19) in patients affected by Red Blood Cell disorders, as hemoglobinopathies (sickle cell disease and thalassaemia), enzymopathies or membranopathies, may be challenging given the rapid spread of the pandemia and limited literature so far, especially in some countries.
At this crucial stage, efforts are being devoted by different initiatives for the generation of documents with indications for the clinical care of these patients. Find the updated list at the new EuroBloodNet section for COVID-19.